Sun Settles With Bausch Over Rifaximin
US Intellectual Property protecting Xifaxan To Remain Intact
Executive Summary
Sun Pharma and Bausch have decided to settle litigation over rifaximin, granting the generics company a non-exclusive license effective 1 January 2028.